Related Experiment Video
Updated: May 5, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
ANKRD2 Knockdown as a Therapeutic Strategy in Osteosarcoma: Effects on Proliferation and Drug Response in U2OS and
Vittoria Cenni1,2, Alberto Bavelloni3, Cristina Capanni1,2
1Institute of Molecular Genetics "Luigi Luca Cavalli-Sforza", National Research Council (IGM-CNR), Unit of Bologna, 40136 Bologna, Italy.
Abstract:
Ankrd2, a mechanoresponsive protein primarily studied in muscle physiology, is emerging as a player in cancer progression. This study investigates the functional role of Ankrd2 in osteosarcoma cells, revealing its critical involvement in cell proliferation and response to chemotherapeutic drugs. We showed that Ankrd2 knockdown impairs the activation of PI3K/Akt and ERK1/2 pathways, reduces levels of cell cycle regulators including cyclin D1 and cyclin B, and counteracts the expression of nuclear lamin A and lamin B, disrupting nuclear morphology and DNA integrity. Strikingly, the loss of Ankrd2 enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin, highlighting Ankrd2 potential as a therapeutic target to improve chemotherapeutic efficacy. Defining a novel mechanistic role for Ankrd2 in promoting tumor progression, we propose that Ankrd2 reduction could be exploited as an adjuvant strategy to enhance the efficacy of chemotherapy, offering new therapeutic opportunities for OS treatment.
Insights
Ankrd2 protein promotes osteosarcoma progression by affecting cell cycle and DNA integrity. Reducing Ankrd2 enhances chemotherapy effectiveness, offering new therapeutic strategies for osteosarcoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Ankrd2 is a mechanoresponsive protein primarily studied in muscle physiology.
- Emerging evidence suggests Ankrd2 plays a role in cancer progression.
Purpose of the Study:
- To investigate the functional role of Ankrd2 in osteosarcoma cells.
- To determine Ankrd2's involvement in cell proliferation and response to chemotherapy.
Main Methods:
- Ankrd2 knockdown in osteosarcoma cells.
- Analysis of PI3K/Akt and ERK1/2 signaling pathways.
- Assessment of cell cycle regulators (cyclin D1, cyclin B).
- Evaluation of nuclear morphology and DNA integrity.
- Testing sensitivity to doxorubicin and cisplatin.
Main Results:
- Ankrd2 knockdown impaired PI3K/Akt and ERK1/2 pathway activation.
- Reduced levels of cyclin D1 and cyclin B were observed after Ankrd2 knockdown.
- Ankrd2 loss disrupted nuclear morphology and DNA integrity.
- Loss of Ankrd2 significantly enhanced osteosarcoma cell sensitivity to doxorubicin and cisplatin.
Conclusions:
- Ankrd2 plays a critical role in osteosarcoma cell proliferation and chemoresistance.
- Ankrd2 is a potential therapeutic target for improving chemotherapy efficacy in osteosarcoma.
- Ankrd2 reduction can be explored as an adjuvant strategy to enhance osteosarcoma treatment outcomes.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...